{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:00:32Z","timestamp":1770822032497,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11864-001-0023-7","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T20:32:53Z","timestamp":1183581173000},"page":"301-308","source":"Crossref","is-referenced-by-count":15,"title":["Organ transplant-related lymphoma"],"prefix":"10.1007","volume":"2","author":[{"given":"Lode J.","family":"Swinnen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/oxfordjournals.ndt.a027077","volume":"11","author":"G Opelz","year":"1996","unstructured":"Opelz G: Are post-transplant lymphomas inevitable? Nephrol Dial Transplant 1996, 11:1952\u20131955.","journal-title":"Nephrol Dial Transplant"},{"key":"23_CR2","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis RE, Travis LB, Rowlings PA, et al.: Risk of lymphoproliferative disorders after bone marrow transplantation: a multiinstitutional study. Blood 1999, 94:2208\u20132216. Reports data from the International Bone Marrow Transplant Registry. Provides detailed information on incidence and risk factors for PTLD in this setting. These are the only populationbased data available for PTLD occurring after allogeneic bone marrow transplantation.","journal-title":"Blood"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJM199012203232502","volume":"323","author":"LJ Swinnen","year":"1990","unstructured":"Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al.: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990, 323:1723\u20131728.","journal-title":"N Engl J Med"},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00007890-198804000-00011","volume":"45","author":"M Ho","year":"1988","unstructured":"Ho M, Jaffe R, Miller G, et al.: The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988, 45:719\u2013727.","journal-title":"Transplantation"},{"key":"23_CR5","first-page":"214","volume":"14","author":"RC Walker","year":"1995","unstructured":"Walker RC, Paya CV, Marshall WF, et al.: Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995, 14:214\u2013221.","journal-title":"J Heart Lung Transplant"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0022-5223(19)34229-1","volume":"105","author":"JM Armitage","year":"1993","unstructured":"Armitage JM, Fricker FJ, del Nido P, et al.: A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg 1993, 105:464\u2013472.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V84.3.972.972","volume":"84","author":"SA Riddler","year":"1994","unstructured":"Riddler SA, Breinig MC, McKnight JL: Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994, 84:972\u2013984.","journal-title":"Blood"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2141.1995.tb08904.x","volume":"89","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Loftin SK, Holladay MS, et al.: Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995, 89:98\u2013103.","journal-title":"Br J Haematol"},{"key":"23_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0011-3840(88)90011-1","volume":"25","author":"MA Nalesnik","year":"1988","unstructured":"Nalesnik MA, Makowka L, Starzl TE: The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988, 25:367\u2013472.","journal-title":"Curr Probl Surg"},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/blood.V86.9.3333.bloodjournal8693333","volume":"86","author":"LJ Swinnen","year":"1995","unstructured":"Swinnen LJ, Mullen GM, Carr TJ, et al.: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995, 86:3333\u20133340.","journal-title":"Blood"},{"key":"23_CR11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","volume":"19","author":"V Leblond","year":"2001","unstructured":"Leblond V, Dhedin N, Mamzer Bruneel MF, et al.: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001, 19:772\u2013778. A large retrospective series that brings some clarity to the relative importance of clinical prognostic factors on the outcome of treatment for PTLD.","journal-title":"J Clin Oncol"},{"key":"23_CR12","first-page":"877","volume":"10","author":"JM Armitage","year":"1991","unstructured":"Armitage JM, Kormos RL, Stuart RS, et al.: Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporinebased immunosuppression. J Heart Lung Transplant 1991, 10:877\u201386.","journal-title":"J Heart Lung Transplant"},{"key":"23_CR13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.1995.13.4.961","volume":"13","author":"V Leblond","year":"1995","unstructured":"Leblond V, Sutton L, Dorent R, et al.: Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995, 13:961\u2013968.","journal-title":"J Clin Oncol"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V85.2.552.552","volume":"85","author":"DM Knowles","year":"1995","unstructured":"Knowles DM, Cesarman E, Chadburn A, et al.: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552\u2013565.","journal-title":"Blood"},{"key":"23_CR15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM198204153061506","volume":"306","author":"DW Hanto","year":"1982","unstructured":"Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al.: Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982, 306:913\u2013918.","journal-title":"N Engl J Med"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9343(94)90043-4","volume":"97","author":"VA Morrison","year":"1994","unstructured":"Morrison VA, Dunn DL, Manivel JC, et al.: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994, 97:14\u201324.","journal-title":"Am J Med"},{"key":"23_CR17","first-page":"91","volume":"5","author":"AH Filipovich","year":"1994","unstructured":"Filipovich AH, Mathur A, Kamat D, et al.: Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994, 5:91\u2013112.","journal-title":"Immunodeficiency"},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1056\/NEJM198805193182013","volume":"318","author":"RS Shapiro","year":"1988","unstructured":"Shapiro RS, Chauvenet A, McGuire W, et al.: Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 1988, 318:1334\u20131334.","journal-title":"N Engl J Med"},{"key":"23_CR19","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1097\/00007890-199812270-00035","volume":"66","author":"CL Davis","year":"1998","unstructured":"Davis CL, Wood BL, Sabath DE, et al.: Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998, 66:1770\u20131779. The authors report on a series of patients treated with a sequential treatment approach. Significant activity for interferon alfa is identified.","journal-title":"Transplantation"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1399-0012.1998.tb01078.x","volume":"12","author":"M Cantarovich","year":"1998","unstructured":"Cantarovich M, Barkun JS, Forbes RD, et al.: Successful treatment of post-transplant lymphoproliferative disorder with interferon-alpha and intravenous immunoglobulin. Clin Transplant 1998, 12:109\u2013115.","journal-title":"Clin Transplant"},{"key":"23_CR21","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJM199105233242102","volume":"324","author":"A Fischer","year":"1991","unstructured":"Fischer A, Blanche S, Le Bidois J, et al.: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991, 324:1451\u20131456.","journal-title":"N Engl J Med"},{"key":"23_CR22","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.V92.9.3137","volume":"92","author":"M Benkerrou","year":"1998","unstructured":"Benkerrou M, Jais JP, Leblond V, et al.: Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998, 92:3137\u20133147. Long-term follow-up on patients treated with a mixture of anti-B-cell monoclonal antibodies, showing the durability of responses to such treatment.","journal-title":"Blood"},{"key":"23_CR23","first-page":"179","volume":"10","author":"AJ Grillo-Lopez","year":"1999","unstructured":"Grillo-Lopez AJ, Lynch J, Coiffier B, et al.: Rituximab therapy of lymphoproliferative disorders in immunosuppressed patients [abstract]. Ann Oncol 1999, 10:179\u2013179.","journal-title":"Ann Oncol"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008372814223","volume":"11","author":"N Milpied","year":"2000","unstructured":"Milpied N, Vasseur B, Parquet N, et al.: Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000, 11:113\u2013116. The largest series of patients treated with rituximab reported so far. A retrospective study, but it indicates a high degree of activity for rituximab in this setting.","journal-title":"Ann Oncol"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V97.6.1590","volume":"97","author":"E Haddad","year":"2001","unstructured":"Haddad E, Paczesny S, Leblond V, et al.: Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001, 97:1590\u20131597.","journal-title":"Blood"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1008263226895","volume":"9","author":"TG Gross","year":"1998","unstructured":"Gross TG, Hinrichs SH, Winner J, et al.: Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy. Ann Oncol 1998, 9:339\u2013340.","journal-title":"Ann Oncol"},{"key":"23_CR27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos EB, Ladanyi M, Emanuel D, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185\u20131191.","journal-title":"N Engl J Med"},{"key":"23_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng CY, et al.: Use of genemodified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9\u201313.","journal-title":"Lancet"},{"key":"23_CR29","unstructured":"Gulley ML, Schneider BG, Swinnen LJ: Origin of post-transplant lymphoproliferative disorder (PTLD) arising in solid organ recipients [abstract]. VIIth International Symposium on Epstein-Barr Virus and Associated Diseases, Stockholm, 1998, 85\u201385."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0023-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-001-0023-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0023-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:16:01Z","timestamp":1737177361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-001-0023-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11864-001-0023-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}